FocalTherics (NASDAQ:FOCL) CFO Kenneth Mobeck Purchases 5,000 Shares

Key Points

• FocalTherics CFO Kenneth Mobeck purchased 5,000 shares at an average price of $4.75, investing $23,750 and increasing his direct holdings by 2.83% to 181,610 shares.
• The company reported a quarterly loss of $0.39 per share, missing analyst estimates by $0.19, despite generating $13.2 million in revenue; analysts expect a full-year loss of $0.78 per share.
• Analyst sentiment is mixed, with an average rating of “Hold” and a consensus price target of $7.75, while institutional investors own 62.74% of the stock.

FocalTherics (NASDAQ:FOCL - Get Free Report) CFO Kenneth Mobeck purchased 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average cost of $4.75 per share, for a total transaction of $23,750.00. Following the completion of the purchase, the chief financial officer directly owned 181,610 shares in the company, valued at $862,647.50. This represents a 2.83% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

FocalTherics Stock Performance

FOCL stock opened at $4.76 on Monday. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40. The business has a 50-day moving average price of $5.39. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The firm has a market cap of $178.40 million, a PE ratio of -4.62 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL - Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.19). The firm had revenue of $13.20 million for the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. As a group, equities analysts forecast that FocalTherics will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

FOCL has been the topic of a number of research reports. Wall Street Zen lowered FocalTherics from a "hold" rating to a "sell" rating in a report on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of FocalTherics in a report on Tuesday, June 2nd. Mizuho set a $15.00 target price on shares of FocalTherics and gave the company an "outperform" rating in a research report on Friday, July 17th. Finally, Piper Sandler reissued a "neutral" rating and issued a $4.00 price target on shares of FocalTherics in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $7.75.

Institutional Trading of FocalTherics

Hedge funds have recently made changes to their positions in the company. SmartHarvest Portfolios LLC acquired a new stake in shares of FocalTherics during the 1st quarter worth approximately $38,000. Lido Advisors LLC acquired a new position in FocalTherics in the first quarter valued at approximately $40,000. Kovack Advisors Inc. purchased a new position in FocalTherics in the fourth quarter worth approximately $53,000. Leonteq Securities AG purchased a new position in FocalTherics in the fourth quarter worth approximately $313,000. Finally, Flax Pond Capital LLC purchased a new position in FocalTherics in the fourth quarter worth approximately $2,623,000. Hedge funds and other institutional investors own 62.74% of the company's stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source